The Lynx Group
Cholangiocarcinoma News

The Cholangiocarcinoma Foundation’s Patient Advocacy Initiatives

March 2022, Vol 3, No 1

At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.

Newly Diagnosed/New to the CCF Program

Ms Bachini presented updates about the newly launched Newly Diagnosed/New to the CCF Program. She said that this program was initiated “because we knew there was a need to reach out to patients and caregivers immediately after their diagnosis. We knew that patients and caregivers needed guidance and resources that we had available for them.”

Ms Bachini reported that at the time of the CCF annual meeting, more than 700 newly diagnosed or newly connected patients with CCA and caregivers have enrolled in the program since its launch in August 2021, noting that “it has been an incredible, successful program.”

The program involves sending an introductory e-mail series that leads patients through the CCF resources and the options that are available to them, a set of positive video interviews with patients and caregivers, and a care kit that “has a lot of goodies in them, and some comfort items, just to let them know that they are not going through this alone.”

Ms Bachini provided details about the characteristics of the database of newly diagnosed patients and new caregivers in the program. In total, 420 patients and 266 caregivers were enrolled in the program. Of these, 331 had a diagnosis of (or represented patients with a diagnosis of) intrahepatic CCA, and 279 were unsure of the exact diagnosis.

The majority (N = 619) of the enrollees had not heard of the CCF before. The majority of the patients were diagnosed between 2020 and 2022, including 127 in 2022, 430 in 2021, and 68 in 2020.

Responding to questions from CCF, the majority of the enrollees concurred that this new program was helpful, providing important information in the following ways:

“Encouraged me to get a second opinion from a CCA specialist”

“Provided me with helpful education materials about CCA”

“Informed me about biomarker testing”

“Offered me hope about long-term survival.”

Additional CCF Initiatives

Ms Bachini provided updates on other CCF initiatives that were launched in recent years.

Support groups. A virtual patient and caregiver support group platform was launched in September 2020. Through this CCF platform, in 2021, 26 support groups were held and included a total of 560 patient and caregiver attendees. Ms Bachini hopes that 50% of newly diagnosed patients with CCA will enroll in 2022.

New research webinar. A webinar series was implemented to inform patients and caregivers about the most up-to-date research, science, and clinical trials. A total of 10 webinars were conducted in 2021 with 1055 registered patients, caregivers, and research advocates, which received 2090 on-demand views.

Nutrition resource. The CCF developed a nutritional and diet resource in partnership with the Oncology Dietician Practice Group (ON DPG), designed specifically for patients with CCA.

As a CCA survivor herself, Ms Bachini said, “Nutrition has always been one of the most asked-about questions from patients and caregivers. And I think it’s because as patients, we feel that that’s the one thing we have some control over during this diagnosis.”

She noted that this resource contains helpful tips, recipes, and guidance about key nutrition principles for patients with CCA.

Patient registry. A new patient registry was launched by the CCF in partnership with Ciitizen (which was later acquired by Invitae), a health technology platform for patient data collection that may be used to advance CCA research, as well as to recruit patients for clinical trials, and help patients collect their medical records at no cost to them.

Related Items

International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research
September 2022, Vol 3, No 3
The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).
Clinical Trial Enrollment Challenges for Patients with Cholangiocarcinoma
By Reham Abdel-Wahab, MD, PhD; Samantha Pear
June/July 2022, Vol 3, No 2
There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.
The International Cholangiocarcinoma Research Network: Educational and Research Achievements
By Reham Abdel-Wahab, MD, PhD
December 2021, Vol 2, No 4
In 2015, the Cholangiocarcinoma Foundation (CCF) launched the International Cholangiocarcinoma Research Network (ICRN). This network is a global collaborative of clinicians, researchers, and scientists from leading academic medical centers and research institutions working together to improve the prevention, early detection, treatment, and prognosis of cholangiocarcinoma (CCA).
New ICD-11 Codes for Cholangiocarcinoma
December 2021, Vol 2, No 4
The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).
Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma
By Melinda Bachini
September/October 2021, Vol 2, No 3
I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.
A Watershed Moment for the Cholangiocarcinoma Community
By Stacie C. Lindsey
June/July 2021, Vol 2, No 2
In an article published last year in CCA News, I shared the Cholangiocarcinoma Foundation (CCF)’s philosophy on taking risks and leveraging collaboration over competition. The CCF was nearing its 15th anniversary, and the FDA had recently approved pemigatinib (Pemazyre), the first targeted therapy approved for cholangiocarcinoma (CCA).
The Urgent Need to Raise Awareness to Cholangiocarcinoma and Fund Research
By Teresa Delcorso-Ellmann
March 2021, Vol 2, No 1
I first learned of cholangiocarcinoma (CCA) in 2015, when my husband Steve was diagnosed with stage IV inoperable intrahepatic CCA and was given a prognosis of less than a year to live. He defied the prognosis and survived for 40 months, until his death in March 2019. When he was diagnosed, neither one of us had ever heard the word “cholangiocarcinoma” and did not know it was possible to have cancer in the bile duct. We both knew that a diagnosis of other gastrointestinal (GI) cancers, such as pancreatic or colon cancer, could be catastrophic and were stunned to realize that the treatment options and outcomes for patients with CCA were the most dismal of all GI cancers.
Where There Is Hope
By Laura R. Hnat
December 2020, Vol 1, No 3
“You have cancer.” These are the 3 little words that everyone dreads hearing and that doctors wish they never had to utter. Yet according to the American Cancer Society, an estimated 1.8 million people will be diagnosed with cancer in the United States this year, and more than 600,000 people will die of it.
Leading the Way to a Paradigm Shift in Cholangiocarcinoma: The International Cholangiocarcinoma Research Network
By Nilo Azad, MD; Mitesh J. Borad, MD
October 2020, Vol 1, No 2
In the past decade, there has been a sea change in awareness about cholangiocarcinoma (CCA). However, the standard of care has remained unchanged for more than 10 years. This year, the FDA approved a new targeted therapy, pemigatinib, which became a treatment option for approximately 10% to 15% of patients with CCA. The process of drug discovery, as well as changes in the standard of care, are becoming increasingly reliant on collaborative approaches that leverage the expertise and resources of a wide range of partners to strengthen the tools and knowledge that advance the research objectives of all stakeholders.
Taking Chances to Drive Innovation in Cholangiocarcinoma Therapy
By Stacie C. Lindsey
August 2020, Vol 1, No 1
The COVID-19 pandemic has changed the way we do business, the way we interact with one another, and other tangible aspects of our work and personal lives. The pandemic has also provided many of us with much-needed time for personal reflection. Often, when we have the opportunity to take a step back, or in this case when we are forced to step back, the result of our thoughtful reflection can be an opportunity to slingshot forward.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: